Tru Niagen — Nicotinamide Riboside

"Nicotinamide riboside, like every NAD+ precursor in consumer supplementation, sits inside a category where mechanistic plausibility is routinely conflated with proven outcome. The Inspectorate entered the Tru Niagen audit expecting overreach, and found the opposite. The brand's parent company has funded and published the largest peer-reviewed clinical research body on the molecule of any consumer entity in the space, and the brand's consumer claims sit visibly inside what that research supports."

"The supporting formulation is minimal — no proprietary blend, no botanical stack, no synergistic-actives narrative that would obscure the underlying molecule. The user is asked to evaluate the supplement on what nicotinamide riboside actually does in the body, not on what an undisclosed combination might do. The rubric rewards this clarity. Material discipline is high. The brand's communications maintain the appropriate epistemic humility about a molecule whose long-term human outcomes are still being measured."

"Two Bio Stars are awarded for the most disciplined entry in a category that frequently embarrasses itself. Transcendent status is withheld because long-term outcome data on NAD+ supplementation remains preliminary — a fact the brand itself acknowledges. The rubric rewards that acknowledgment as part of the institutional posture excellence requires."